FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210866519> ?p ?o ?g. }

• W3210866519 endingPage "203" @default.
• W3210866519 startingPage "193" @default.
• W3210866519 abstract "Modulating the DNA damage response and repair (DDR) pathways is a promising strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related protein, which is crucial for DDR.This phase II trial evaluated ceralasertib plus durvalumab for the treatment of patients with metastatic melanoma who had failed anti-programmed cell death protein 1 therapy.Among the 30 patients, we observed an overall response rate of 31.0% and a disease control rate of 63.3%. Responses were evident across patients with acral, mucosal, and cutaneous melanoma. The median duration of response was 8.8 months (range, 3.8-11.7 months). The median progression-free survival was 7.1 months (95% confidence interval, 3.6-10.6 months), and the median overall survival was 14.2 months (95% confidence interval, 9.3-19.1 months). Common adverse events were largely hematologic and manageable with dose interruptions and reductions. Exploratory biomarker analysis suggested that tumors with an immune-enriched microenvironment or alterations in the DDR pathway were more likely to respond to the study treatment.We conclude that ceralasertib in combination with durvalumab has promising antitumor activity among patients with metastatic melanoma who have failed anti-programmed cell death protein 1 therapy, and constitute a population with unmet needs." @default.
• W3210866519 created "2021-11-08" @default.
• W3210866519 creator A5009542188 @default.
• W3210866519 creator A5010584350 @default.
• W3210866519 creator A5017213600 @default.
• W3210866519 creator A5020754942 @default.
• W3210866519 creator A5021762206 @default.
• W3210866519 creator A5025187591 @default.
• W3210866519 creator A5028617609 @default.
• W3210866519 creator A5030995134 @default.
• W3210866519 creator A5033310499 @default.
• W3210866519 creator A5036175630 @default.
• W3210866519 creator A5056480807 @default.
• W3210866519 creator A5062162923 @default.
• W3210866519 creator A5067438829 @default.
• W3210866519 date "2022-02-01" @default.
• W3210866519 modified "2023-10-17" @default.
• W3210866519 title "Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy" @default.
• W3210866519 cites W1942954494 @default.
• W3210866519 cites W1944707476 @default.
• W3210866519 cites W1999574084 @default.
• W3210866519 cites W2028433016 @default.
• W3210866519 cites W2043115278 @default.
• W3210866519 cites W2066671159 @default.
• W3210866519 cites W2103441770 @default.
• W3210866519 cites W2104549677 @default.
• W3210866519 cites W2107916366 @default.
• W3210866519 cites W2119180969 @default.
• W3210866519 cites W2122732537 @default.
• W3210866519 cites W2123363005 @default.
• W3210866519 cites W2123879591 @default.
• W3210866519 cites W2128035403 @default.
• W3210866519 cites W2138601221 @default.
• W3210866519 cites W2152897456 @default.
• W3210866519 cites W2153466677 @default.
• W3210866519 cites W2166662937 @default.
• W3210866519 cites W2169456326 @default.
• W3210866519 cites W2276335691 @default.
• W3210866519 cites W2332292689 @default.
• W3210866519 cites W2417483443 @default.
• W3210866519 cites W2477512277 @default.
• W3210866519 cites W2598814171 @default.
• W3210866519 cites W2613155082 @default.
• W3210866519 cites W2748949248 @default.
• W3210866519 cites W2767551096 @default.
• W3210866519 cites W2796408191 @default.
• W3210866519 cites W2867868648 @default.
• W3210866519 cites W2897726163 @default.
• W3210866519 cites W2952406594 @default.
• W3210866519 cites W2972535107 @default.
• W3210866519 cites W2985799850 @default.
• W3210866519 cites W3014748351 @default.
• W3210866519 cites W3022071200 @default.
• W3210866519 cites W3028793019 @default.
• W3210866519 cites W3161453886 @default.
• W3210866519 cites W3162215872 @default.
• W3210866519 cites W3168647721 @default.
• W3210866519 doi "https://doi.org/10.1016/j.annonc.2021.10.009" @default.
• W3210866519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34710570" @default.
• W3210866519 hasPublicationYear "2022" @default.
• W3210866519 type Work @default.
• W3210866519 sameAs 3210866519 @default.
• W3210866519 citedByCount "46" @default.
• W3210866519 countsByYear W32108665192021 @default.
• W3210866519 countsByYear W32108665192022 @default.
• W3210866519 countsByYear W32108665192023 @default.
• W3210866519 crossrefType "journal-article" @default.
• W3210866519 hasAuthorship W3210866519A5009542188 @default.
• W3210866519 hasAuthorship W3210866519A5010584350 @default.
• W3210866519 hasAuthorship W3210866519A5017213600 @default.
• W3210866519 hasAuthorship W3210866519A5020754942 @default.
• W3210866519 hasAuthorship W3210866519A5021762206 @default.
• W3210866519 hasAuthorship W3210866519A5025187591 @default.
• W3210866519 hasAuthorship W3210866519A5028617609 @default.
• W3210866519 hasAuthorship W3210866519A5030995134 @default.
• W3210866519 hasAuthorship W3210866519A5033310499 @default.
• W3210866519 hasAuthorship W3210866519A5036175630 @default.
• W3210866519 hasAuthorship W3210866519A5056480807 @default.
• W3210866519 hasAuthorship W3210866519A5062162923 @default.
• W3210866519 hasAuthorship W3210866519A5067438829 @default.
• W3210866519 hasBestOaLocation W32108665191 @default.
• W3210866519 hasConcept C121608353 @default.
• W3210866519 hasConcept C126322002 @default.
• W3210866519 hasConcept C143998085 @default.
• W3210866519 hasConcept C197934379 @default.
• W3210866519 hasConcept C2777054765 @default.
• W3210866519 hasConcept C2777658100 @default.
• W3210866519 hasConcept C2777701055 @default.
• W3210866519 hasConcept C2777742743 @default.
• W3210866519 hasConcept C2780030458 @default.
• W3210866519 hasConcept C2781230642 @default.
• W3210866519 hasConcept C2908647359 @default.
• W3210866519 hasConcept C502942594 @default.
• W3210866519 hasConcept C71924100 @default.
• W3210866519 hasConcept C99454951 @default.
• W3210866519 hasConceptScore W3210866519C121608353 @default.
• W3210866519 hasConceptScore W3210866519C126322002 @default.
• W3210866519 hasConceptScore W3210866519C143998085 @default.

• next